NattoPharma

OVERVIEW |  NEWS |  MULTIMEDIA  | RESEARCH

---

NattoPharma Company Summary

COMPANY DATA

	Homepage	www.nattopharma.com

---

Key Developments: NattoPharma

	EFSA Opinion Strengthens Platform For NattoPharma (OSL:NATTO) 's MenaQ7(TM) In Europe NOV 17, 2008 18:07 - Article Views: 525 NattoPharma (OSL:NATTO) (Lysaker, Norway 17 November 2008) The European Food Safety Authority (EFSA) has published a positive scientific opinion on vitamin K2, MK-7 from natto as a dietary supplement and food ingredient. The positive EFSA-opinion gives NattoPharma ASA a solid platform for wide distribution of MenaQ7(TM) in Europe.
	NattoPharma (OSL:NATTO) Low Vitamin K2 Status Is A Risk Factor For Hardening Of The Arteries - Presented At The American Society Of Nephrology Convention NOV 13, 2008 19:57 - Article Views: 602 NattoPharma (OSL:NATTO) 13 November 2008, Lysaker, Norway -NattoPharma and PL Thomas, announced significant exposure and discussion of Vitamin K2 and its role in promoting cardiovascular health at the American Society of Nephrology's Renal Week 2008 in Philadelphia. Of note, four key presentations, including two abstracts, a poster and a feature presentation by Leon Schurgers, PhD, Senior Scientist at the Cardiovascular Research Institute Maastricht (CARIM) at the University of Maastricht, all discussed the significance of adequate vitamin K2 intake for the prevention of vascular calcification in both healthy and diseased populations. The source of natural vitamin K2 used in the studies was MenaQ7, natural vitamin K2.
	NattoPharma (OSL:NATTO) BONE QUALITY IN CHILDREN MAY BE COMPRISED BY THERAPY WITH VITAMIN K-ANTAGONISTS OCT 14, 2008 20:41 - Article Views: 356 NattoPharma (OSL:NATTO) 14.10.2008, Lysaker, Norway - NattoPharma would like to notify a new publication by Avgeri et al. (J Pediatr Hematol Oncol), about the association of long-term oral anticoagulant therapy (OAC) resulting in a remarkable reduction in bone mineral density and significant impairment in other bone health parameters.
	NattoPharma (OSL:NATTO) Acquires MGP Diagnostics And Secures Rights To Important Patent OCT 14, 2008 19:17 - Article Views: 556 NattoPharma (OSL:NATTO) NattoPharma ASA has acquired all shares of MGP Diagnostics AS, securing ownership of a granted patent that is the key to the development of a new diagnostic test concept. This concept may determine the need for the natural vitamin K2 product Mena Q7(TM), to which NattoPharma has exclusive rights.
	NattoPharma (OSL:NATTO) Secures New Distribution Agreement SEP 12, 2008 00:55 - Article Views: 733 NattoPharma (OSL:NATTO) (Lysaker, Norway, 11 September 2008) NattoPharma ASA has entered into an exclusive distribution agreement with Pathway International Pty Ltd for the natural K2 vitamin product MenaQ7(TM) in Australia and New Zealand. The agreement is an important element in NattoPharma's strategy to ensure global distribution of MenaQ7(TM).
	NattoPharma (OSL:NATTO) ARTERIAL CALCIFICATION REDUCED WITH VITAMIN K2 INTAKE ACCORDING TO NEW STUDY IN THE JOURNAL ATHEROSCLEROSIS SEP 10, 2008 18:17 - Article Views: 291 NattoPharma (OSL:NATTO) 10th of September 2008, Lysaker - NattoPharma and PL Thomas are pleased to announce that a new study demonstrated the association of high dietary Vitamin K2 consumption with reduction of coronary calcification in humans. Accepted by the journal Atherosclerosis, this study is now available online. http://www.atherosclerosis-journal.com/article/S0021-9150(08)00507-8/abstract
	Q2 Report 2008 NattoPharma (OSL:NATTO) ASA AUG 28, 2008 20:35 - Article Views: 236 NattoPharma (OSL:NATTO)
	NattoPharma (OSL:NATTO) Has Received The "2008 Frost & Sullivan Product Innovation Of The Year Award" AUG 22, 2008 17:27 - Article Views: 719 NattoPharma (OSL:NATTO) NattoPharma ASA and PL Thomas proudly announce that NattoPharma's natural vitamin K2 product, MenaQ7(TM), has received the prestigious 2008 Frost & Sullivan Product Innovation of the Year Award in the North American Vitamin market. According to Frost & Sullivan "The award is in recognition of the company's unique capability to develop natural vitamin K2 as MenaQ7(TM) with established and proven bone and heart health benefits. Owing to its natural form coupled with superb bioavailability, MenaQ7 obtained excellent market acceptance."
	Presentation Of Q2 2008 NattoPharma (OSL:NATTO) AUG 20, 2008 00:01 - Article Views: 158 NattoPharma (OSL:NATTO) On behalf of NattoPharma, Orion Securities would like to invite shareholders, investors and other interested parties to a lunch presentation in connection with the release of NattoPharma ASA's second quarter results 2008.
	Vitamin K Deficiency May Be A Significant Risk Factor For Low Bone Mass In Healthy Children And In Those With Juvenile Arthritis JULY 16, 2008 17:43 - Article Views: 908 NattoPharma 16 July 2008, Lysaker, Norway - NattoPharma and PL Thomas announce today a new study has published in the journal Clinical and Experimental Rheumatology 2008; 26(3):484-91) discussing the association between the vitamin K-dependent protein osteocalcin and the incidence of low bone mass in children with juvenile idiopathic arthritis.

629 COMPANY PROFILE VIEWS

This Page Viewed: (Last 7 Days: 6) (Last 30 Days: 30) (Since Published: 629)